IMMUNE EFFECTOR MECHANISMS IN EBV CARRYING PATIENTS

这个项目涉及EB病毒感染者之间的相互作用 细胞和宿主免疫系统在正常和免疫缺陷 人士 为了更好地理解这个复杂的系统， 有必要扩大我们对相互作用的认识， 病毒与不同宿主细胞在体外和体内， 病毒感染细胞和宿主之间的相互作用。 这 该项目旨在分析这两个层面的某些问题， 相互关联的方式。 该项目由以下部分组成： I. 病毒-细胞-宿主系统分析 二. 临床相关研究。 第一部分：1。 现在继续研究这六种蛋白质 已知与EBV转化的B细胞相关，EBNA-1-5 LMP; 2。LCL和BL之间的表型相关差异 亚型和这种差异在鉴别肿瘤中的作用 前体细胞的起源，以及靶细胞对MHC- 限制性细胞毒性T细胞; 3.效应机制介导 针对EBV转化细胞的免疫监视; 4. 一些 EBV-B细胞的相互作用。 第三部分将重点放在：1。方法上的发展， 体内潜伏性EBV感染细胞的展示; 2. EB病毒携带B细胞的鉴定和特征 体内; 3.急性单核细胞增多症期间效应物动员， 与沉默血清转化相比; 4. EBV特异性和非特异性 免疫缺陷患者的特异性效应子分析， 控制潜伏性EBV感染的B细胞的增殖; 5.主持人- 艾滋病或艾滋病相关疾病患者与EBV-B细胞的关系 复合物（ARC）; 6.鼻咽部抗原表达研究 carcinoma.

This project deals with the interactions between EBV-infected cells and the host immune system in normal and immunodefective persons. For an improved understanding of this complex system, it is necessary to broaden our knowledge both on the interaction of the virus with different host cells in vitro and in vivo, and on the interplay between the virally infected cells and the host. This project aims at the analysis of certain questions at both levels, in a mutually interrelated way. The project consists of the following parts: I. Analysis of the virus-cell-host system II. Clinically related studies. Part I will deal with: 1. Continued study of the six proteins now known to be associated with EBV-transformed B cells, EBNA-1-5 and LMP; 2. Phenotype related differences between LCL and BL subtypes and role of such differences for identifying the tumor precursor cell of origin, and for target cell sensitivity to MHC- restricted cytotoxic T-cells; 3. Effector mechanisms mediating immune surveillance against EBV transformed cells; 4. Some aspects of the EBV-B cell interaction. Part III will focus on: 1. Methodological developments aimed at the demonstration of latently EBV-infected cells in vivo; 2. Identification and characterization of EBV carrying B-cells in vivo; 3. Effector mobilization during acute mononucleosis, compared to silent seroconversion; 4. EBV specific and non specific effector analysis in immunodefectives that can or cannot control the proliferaton of latently EBV-infected B-cells; 5. Host- EBV-B cell relationships in patients with AIDS or AIDS-related complex (ARC); 6. Antigen expression studies in nasopharyngeal carcinoma.